Shanghai Bio-heart Biological Technology Co., Ltd. (2185)

Overview

Shanghai Bio-heart Biological Technology Co., Ltd. is a pioneer in the interventional cardiovascular device industry within the People's Republic of China. Founded in 2014 and headquartered in Shanghai, this company is at the forefront of developing groundbreaking technologies aimed at revolutionizing the treatment of cardiovascular diseases. With a core focus on bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies, Shanghai Bio-heart is dedicated to addressing the complex challenges of coronary artery diseases and uncontrolled and resistant hypertension. In addition to its innovative product pipeline, the company has established a strategic collaboration with Terumo (China) Investment Co., Ltd., enhancing its capacity to advance clinical trials and bring cutting-edge medical solutions to the market.

Products and Services

• Bioheart BRS System - This bioresorbable scaffold system represents a significant advancement in the treatment of coronary artery disease. Designed to be used in percutaneous coronary intervention (PCI) procedures, the Bioheart system aids in the opening of narrowed arteries, providing a temporary scaffold that is gradually absorbed by the body. This innovative treatment aims to restore blood flow while promoting natural vessel healing and reducing long-term complications associated with permanent metal stents.
• Iberis 2nd - This product candidate is a multi-electrode renal denervation (RDN) therapy, which is a minimally invasive procedure targeting the nerves around the kidneys to reduce blood pressure in patients with uncontrolled and resistant hypertension. The development of Iberis 2nd underscores the company's commitment to providing alternative treatment solutions for hypertension, a condition that significantly increases the risk of heart disease, stroke, and kidney failure.
• Drug Coated Balloon - The sirolimus drug-eluting balloon catheter is designed for the treatment of in-stent restenosis, a condition where previously treated arteries become narrowed again. This product combines the mechanical benefit of a traditional balloon catheter dilatation with the local delivery of a drug that prevents cell proliferation, thereby minimizing the chance of restenosis. The drug-coated balloon represents a significant innovation in the field of coronary artery disease treatment, providing an effective alternative for patients experiencing complications from earlier interventions.